Table 3.
Characteristics of patients treated with antibiotic regimens including or sparing tigecycline
| Tigecycline‐including regimens | Tigecycline‐sparing regimens | |
|---|---|---|
| Nr. of patients | 29 | 71 |
| Acute myeloid leukemia‐related factors | ||
| Baseline risk classification | ||
| Karyotype cytogenetics | ||
| Favorable | 6 (20.7) | 16 (22.5) |
| Intermediate | 15 (51.7) | 34 (47.9) |
| Unfavorable | 8 (27.6) | 21 (29.6) |
| Secondary acute myeloid leukemia | 1 (3.4) | 3 (4.2) |
| Blast crisis | — | 1 (1.4) |
| Failure to achieve CR by day 15 and/or by day 28 | 7 (24.1) | 16 (22.5) |
| Host‐related factors at start of remission induction chemotherapy | ||
| ECOG performance status ≥ 2 | — | 1 (1.4) |
| Patient age ≥ 50 | 12 (41.4) | 32 (45.1) |
| Gender (Male) | 18 (62) | 48 (67.6) |
| Subjects with inadequate renal functiona | — | 1 (1.4) |
| Subjects with inadequate liver functionb | 1 (3.4) | 2 (2.8) |
| Subjects with clinically significant cardiac diseasec | — | 1 (1.4) |
| Year of NEC diagnosis | ||
| Median (range) | 2010 (2007–2012) | 2005 (2002–2012) |
| Ultrasonography features | ||
| Bowel wall thickness | ||
| Median (range), mm | 12.5 (6–20) | 11 (6–19) |
| Microbiological findings | 8 (27.6) | 18 (25.3) |
| Escherichia coli | 3 (10.3) | 7 (9.8) |
| ESBL‐producing strains | 3 (10.3) | 2 (2.8) |
| Klebsiella pneumoniae | 3 (10.3) | 4 (5.6) |
| KPC‐producing strains | 3 (10.3) | — |
| Streptococcus mutans | — | 3 (4.2) |
| Enterococcus faecium | 2 (6.9) | 1 (1.4) |
| Glycopeptide‐resistant | 2 (6.9) | 1 (1.4) |
| Pseudomonas aeruginosa | — | 1 (1.4) |
| Candida albicans | — | 2 (2.8) |
| Abdominal surgery | — | 6 (8.4) |
| Admission in intensive care unit | 1 (3.4) | 7 (9.8) |
| Death | 2 (6.9) | 21 (29.6) |
Unless otherwise specified data refer to the number of patients.
CR, complete remission; ECOG, Eastern Cooperative Oncology group.
All patients received antimicrobial prophylaxis with oral levofloxacin (500 mg daily) and antimold agents (oral itraconazole (400 mg daily) or posaconazole [600 mg daily]).
a
Serum creatinine ≥ 1.5 mg/dL or eGFR < 59 mL/min.
b
Aspartate Aminotranferase (AST) and/or Alanine Aminotransferase (ALT) and/or direct bilirubin ≥ 2.5 × upper limit of normal (ULN).
c
Left ventricular ejection fraction ≤ 45%.